WellGen has been called out as an innovator by a Global Business Insights industry report. WellGen is developing propeirtary nutraceuticals for medical foods, a market described as a high potential growth area for the future.
North Brunswick, NJ (PRWEB) November 17, 2009 -- A newly released industry analysis highlights WellGen, Inc. as an important innovator in a high growth market. The report describes the significant business potential in nutraceuticals, and distinguishes WellGen among a select group of start-up companies leading innovation in this emerging market. The report entitled, “Key Players and Innovative Start-Ups in Nutraceuticals” analyzes companies engaged in commercializing nutraceuticals, including Nestlé, Danone, Abbott, DSM, and Provexis. The in-depth report was published by Business Insights a leading provider of strategic analysis of innovation in health and wellness.
The report describes the WellGen business model and WellGen’s lead medical food candidate (WG0401):
“The company’s first product – a theaflavin rich black tea concentrate (WG0401) – is an anti-inflammatory agent that, among other effects, decreases expression of cyclooxygenase-2 (COX-2). COX-2 was the target of multi-billion dollar pharma compounds such as Vioxx, which has been withdrawn from the market for safety reasons. In contrast to Vioxx, WG0401 modulates a number of pro- and anti-inflammatory genes essential to help the body respond to and recover from inflammatory challenges such as intense exercise or illness.”
Commenting on WellGen’s plans for developing medical foods, chief executive officer, Dr. Roddy Carter, MD said, “Despite excellent medical care, there are a large number of major inflammation-related conditions that still challenge us with residual pathology. For WellGen, medical foods will enable us to provi
Copyright©2009 Vocus, Inc.
All rights reserved